journal
MENU ▼
Read by QxMD icon Read
search

Nature Reviews. Clinical Oncology

journal
https://www.readbyqxmd.com/read/28631738/breast-cancer-olaparib-improves-pfs
#1
Diana Romero
No abstract text is available yet for this article.
June 20, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28631737/haematological-cancer-brentuximab-vedotin-a-new-standard-for-cutaneous-t-cell-lymphoma
#2
David Killock
No abstract text is available yet for this article.
June 20, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28631736/haematological-cancer-staging-and-restaging-patients-with-lymphoma-a-better-approach
#3
Vijaya R Bhatt, James O Armitage
No abstract text is available yet for this article.
June 20, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28607521/haematological-cancer-where-are-we-now-with-the-treatment-of-multiple-myeloma
#4
Gareth J Morgan, Leo Rasche
No abstract text is available yet for this article.
June 13, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28607519/breast-cancer-microenvironment-mediates-differential-resistance
#5
Peter Sidaway
No abstract text is available yet for this article.
June 13, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28607518/independent-imaging-biomarkers-do-not-exist
#6
Harry B Burke
No abstract text is available yet for this article.
June 13, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28607517/immunotherapy-exploiting-pd-1-on-tams-for-tumour-cell-kill
#7
Lisa Hutchinson
No abstract text is available yet for this article.
June 13, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28607516/immunotherapy-neuropilin-1-is-required-for-treg-stability
#8
Peter Sidaway
No abstract text is available yet for this article.
June 13, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28607514/evolution-of-lymphoma-staging-and-response-evaluation-current-limitations-and-future-directions
#9
REVIEW
Joel Cunningham, Sunil Iyengar, Bhupinder Sharma
The accurate detection and precise assessment of therapeutic responses is critical to the optimal management of patients with lymphoma. Over the past 50 years, dramatic advances in technology have established imaging as the cornerstone of disease evaluation. However, the appropriate application of current techniques requires acknowledgement of their strengths and weaknesses, and appreciation of the full diversity of lymphoid neoplasms. The role of anatomical and functional imaging in detection, treatment escalation/de-escalation and prognostication of patients with lymphoma can be misinterpreted...
June 13, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28607513/haematological-cancer-genomic-disruption-of-cd7-avoids-fractricide
#10
Peter Sidaway
No abstract text is available yet for this article.
June 13, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28561073/targeted-therapies-j-alex-hints-at-new-first-line-in-nsclc
#11
Lisa Hutchinson
No abstract text is available yet for this article.
May 31, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28561072/immunotherapy-macrophages-hijack-anti-pd-1-therapy
#12
David Killock
No abstract text is available yet for this article.
May 31, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28561071/clinical-utility-of-gene-expression-signatures-in-early-stage-breast-cancer
#13
REVIEW
Maryann Kwa, Andreas Makris, Francisco J Esteva
Breast cancer is a heterogeneous disease, with different subtypes having a distinct biological, molecular, and clinical course. Assessments of standard clinical and pathological features have traditionally been used to determine the use of adjuvant systemic therapy in patients with early stage breast cancer; however, the ability to identify those who will benefit from adjuvant chemotherapy remains a challenge, leading to the overtreatment of some patients. Advances in molecular medicine have substantially improved the accuracy of gene-expression profiling of breast tumours, resulting in improvements in the ability to predict a patient's risk of breast cancer recurrence and likely response to endocrine therapy and/or chemotherapy...
May 31, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28534531/unravelling-the-biology-of-sclc-implications-for-therapy
#14
REVIEW
Joshua K Sabari, Benjamin H Lok, James H Laird, John T Poirier, Charles M Rudin
Small-cell lung cancer (SCLC) is an aggressive malignancy associated with a poor prognosis. First-line treatment has remained unchanged for decades, and a paucity of effective treatment options exists for recurrent disease. Nonetheless, advances in our understanding of SCLC biology have led to the development of novel experimental therapies. Poly [ADP-ribose] polymerase (PARP) inhibitors have shown promise in preclinical models, and are under clinical investigation in combination with cytotoxic therapies and inhibitors of cell-cycle checkpoints...
May 23, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28534529/scientific-advice-is-drug-repurposing-missing-a-trick
#15
Pan Pantziarka
No abstract text is available yet for this article.
May 23, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28534528/combining-drugs-and-extending-treatment-a-pfs-end-point-is-not-sufficient
#16
Bishal Gyawali, Vinay Prasad
No abstract text is available yet for this article.
May 23, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28508875/early-phase-clinical-trials-of-anticancer-agents-in-children-and-adolescents-an-itcc-perspective
#17
REVIEW
Lucas Moreno, Andrew D J Pearson, Xavier Paoletti, Irene Jimenez, Birgit Geoerger, Pamela R Kearns, C Michel Zwaan, Francois Doz, Andre Baruchel, Josef Vormoor, Michela Casanova, Stefan M Pfister, Bruce Morland, Gilles Vassal
In the past decade, the landscape of drug development in oncology has evolved dramatically; however, this paradigm shift remains to be adopted in early phase clinical trial designs for studies of molecularly targeted agents and immunotherapeutic agents in paediatric malignancies. In drug development, prioritization of drugs on the basis of knowledge of tumour biology, molecular 'drivers' of disease and a drug's mechanism of action, and therapeutic unmet needs are key elements; these aspects are relevant to early phase paediatric trials, in which molecular profiling is strongly encouraged...
May 16, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28440331/immunotherapy-does-adjuvant-ipilimumab-have-little-adverse-effect-on-quality-of-life
#18
Paul Lorigan, Adele C Green
No abstract text is available yet for this article.
April 25, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28397828/emt-cscs-and-drug-resistance-the-mechanistic-link-and-clinical-implications
#19
REVIEW
Tsukasa Shibue, Robert A Weinberg
The success of anticancer therapy is usually limited by the development of drug resistance. Such acquired resistance is driven, in part, by intratumoural heterogeneity - that is, the phenotypic diversity of cancer cells co-inhabiting a single tumour mass. The introduction of the cancer stem cell (CSC) concept, which posits the presence of minor subpopulations of CSCs that are uniquely capable of seeding new tumours, has provided a framework for understanding one dimension of intratumoural heterogeneity. This concept, taken together with the identification of the epithelial-to-mesenchymal transition (EMT) programme as a critical regulator of the CSC phenotype, offers an opportunity to investigate the nature of intratumoural heterogeneity and a possible mechanistic basis for anticancer drug resistance...
April 11, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28374786/targeted-agents-and-immunotherapies-optimizing-outcomes-in-melanoma
#20
REVIEW
Jason J Luke, Keith T Flaherty, Antoni Ribas, Georgina V Long
Treatment options for patients with metastatic melanoma, and especially BRAF-mutant melanoma, have changed dramatically in the past 5 years, with the FDA approval of eight new therapeutic agents. During this period, the treatment paradigm for BRAF-mutant disease has evolved rapidly: the standard-of-care BRAF-targeted approach has shifted from single-agent BRAF inhibition to combination therapy with a BRAF and a MEK inhibitor. Concurrently, immunotherapy has transitioned from cytokine-based treatment to antibody-mediated blockade of the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and, now, the programmed cell-death protein 1 (PD-1) immune checkpoints...
April 4, 2017: Nature Reviews. Clinical Oncology
journal
journal
20200
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"